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Abstract A series of deletion mutants was created to analyze
the function of the membrane-proximal region of the cytoplasmic
tail of the rat type 1a (AT1a) angiotensin receptor. In transiently
transfected COS-7 cells, the truncated mutant receptors showed
a progressive decrease in surface expression, with no major
change in binding affinity for the peptide antagonist,
[Sar1,Ile8]angiotensin II. In parallel with the decrease in receptor
expression, a progressive decrease in angiotensin II-induced
inositol phosphate responses was observed. Alanine substitutions
in the region 307^311 identified the highly conserved
phenylalanine309 and adjacent lysine residues as significant
determinants of AT1a receptor expression.
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1. Introduction
The type 1 (AT1) angiotensin II receptor is a G protein-
coupled receptor (GPCR), that mediates the cardiovascular
and other actions of the octapeptide hormone, angiotensin
II (Ang II). Agonist binding to the AT1 receptor stimulates
phospholipase C activation via the Gq family of G proteins,
and promotes rapid internalization of the receptor [1,2]. Sev-
eral conserved amino acids, mostly located in the membrane
domains, are important determinants of GPCR function [3,4].
The membrane-proximal region of the cytoplasmic tail of
many GPCRs contains a conserved aromatic residue and
one or more positively charged adjacent amino acids. The
function of the membrane-proximal region that includes these
conserved structural elements was analyzed in the rat AT1a
angiotensin receptor.
It has been demonstrated that the carboxyl-terminal tail of
several GPCRs has a critical role in coupling of the receptor
with its cognate G protein(s) [5^7]. In the L2 adrenergic re-
ceptor and endothelin receptors, palmitoylation on cysteine
residues of the cytoplasmic tail is required for G protein cou-
pling [8^10]. In addition to palmitoylation, other structural
elements in this region have been implicated in G protein
coupling of adrenergic receptors [5], the substance P receptor
[11], and endothelin receptors [8,10]. However, the participa-
tion of the carboxyl-terminal tail in G protein activation is not
a general requirement for GPCR signaling. Truncation of the
cytoplasmic tail did not a¡ect second messenger generation by
several GPCRs, including many Ca2 mobilizing receptors,
such as the C5a [12], parathyroid [13], neurotensin [14] and
neurokinin-2 receptors [15]. Also, the GnRH receptor, a
GPCR that lacks a cytoplasmic tail, shows normal G protein
coupling and inositol phosphate signal generation [16].
The carboxyl-terminal tail of many GPCRs is also required
for receptor internalization and desensitization [17]. However,
the structural determinants for these processes appear to be
di¡erent from those of G protein coupling. Serine-threonine
rich regions, located relatively distant from the membrane
domain in the cytoplasmic tail and in the third intracellular
loop, are the major requirements for receptor internalization
and desensitization in many GPCRs [5,17].
Reduced expression levels after deletions of the carboxyl-
terminal tail have been reported for many GPCRs, including
rhodopsin [18], L2-adrenergic [19], muscarinic [20], histamine
H2 [21], neurokinin [22], C5a anaphylatoxin[12], parathyroid
hormone [13] and AT1 angiotensin [23,24] receptors. These
¢ndings indicate that the cytoplasmic tail may be a major
determinant of the expression of GPCRs on the cell surface.
Previous studies have demonstrated the importance of the
carboxyl-terminal tail in internalization of the AT1 receptor
[25^27]. However, the role of the cytoplasmic tail in AT1
receptor signaling and expression is more controversial. It is
generally agreed that C-terminal deletions of the cytoplasmic
tail up to position 314 do not interfere with signal generation
by the AT1 receptor [23,26,28]. Larger deletions of the cyto-
plasmic tail have been found to impair the inositol phosphate
responses of the rat AT1a receptor [29,30]. However, a study
on the human AT1 receptor reported that the cytoplasmic tail
is selectively required for Gi activation without a¡ecting Gq-
mediated inositol phosphate responses [24]. Although an ear-
lier report described normal expression levels after deletion of
the cytoplasmic tail of the rat AT1a receptor [29], other studies
of rat AT1a [23] and human AT1 [24] receptors found that
truncation of the cytoplasmic tail decreased the expression
level of the receptor.
The aim of the present study was to further investigate the
role of the membrane-proximal portion of the carboxyl-termi-
nal tail in AT1a receptor expression and activation, and to
identify the functions of conserved amino acids in this region.
2. Materials and methods
2.1. Mutagenesis and expression of the rat smooth muscle AT1a
receptor cDNA
The cDNA of the rat smooth muscle AT1a receptor (kindly pro-
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vided by Kenneth E. Bernstein [31]) was subcloned into the mamma-
lian expression vector pcDNAI/Amp (Invitrogen, San Diego, CA) as
described earlier [32]. Mutant AT1a receptors were created using the
Mutagene kit (Bio-Rad). The sequences of the mutants were identi¢ed
by dideoxy sequencing using Sequenase II (Amersham). The COS-7
cells were transiently transfected with plasmids containing wild-type
or mutant AT1a receptor cDNAs using Lipofectamine (Life Technol-
ogies) as described previously [33].
2.2. Inositol phosphate measurements
The culture medium was replaced 24 h after transfection with 0.5 ml
of inositol-free Dulbecco’s modi¢ed Eagle’s medium (DMEM) con-
taining 1 g/l bovine serum albumin, 20 WCi/ml myo-[2-3H]inositol
(Amersham), 2.5% fetal calf serum, 100 IU/ml penicillin, and 100 Wg/
ml streptomycin. 24 h later the cells were washed twice, incubated in
inositol-free DMEM in the presence of 10 mM LiCl for 30 min at
37‡C, and stimulated with 1 WM Ang II for 20 min. Inositol phos-
phates were extracted as described earlier [32], and after neutralization
the samples were applied to Bio-Rad AG 1-X8 columns. The columns
were washed three times with 3 ml water and twice with 3 ml 0.2 M
ammonium-formate in 0.1 M formic acid. After these washing steps,
the combined InsP2+InsP3 fractions were eluted with 2U3 ml 1 M
ammonium formate in 0.1 M formic acid, and radioactivities were
detected by liquid scintillation counting.
2.3. [Sar1,Ile8]Ang II binding to intact cells
The number of Ang II binding sites was determined by incubating
the transfected cells with 125I-[Sar1,Ile8]Ang II (Hazleton Laborato-
ries, Vienna, VA or DuPont-NEN) and increasing concentrations of
unlabeled [Sar1,Ile8]Ang II in DMEM containing 25 mM HEPES (pH
7.4) for 6 h at 4‡C. The cells were washed twice with ice-cold phos-
phate-bu¡ered saline, and the radioactivity associated with the cells
was measured by Q-spectrometry. The displacement curves were ana-
lyzed with the Ligand computer program using a one-site model [34].
2.4. Receptor internalization in transiently transfected COS-7 cells
To determine the internalization kinetics of the mutant and wild-
type AT1a receptors 125I-Ang II was added to HEPES-bu¡ered
DMEM, and the cells were incubated at 37‡C for the indicated times.
Incubations were stopped by placing the cells on ice and rapidly
washing them twice with ice-cold phosphate-bu¡ered saline. Acid-re-
leased and acid-resistant radioactivities were separated and measured
by Q-spectrometry as described earlier [32]. The percent of internalized
ligand at each time point was calculated from the ratio of the acid-
resistant speci¢c binding to the total (acid-resistant+acid-released)
speci¢c binding.
3. Results and discussion
3.1. [Sar1,Ile8]Ang II binding to cytoplasmic tail deletion
mutant AT1a receptors
Deletion mutant AT1a receptors were created to study the
membrane-proximal region (position 307^319) of the cyto-
plasmic tail (Fig. 1) by substituting the indicated amino acid
with a stop codon (e.g. substitution of Tyr319 with a stop
codon =v319). To determine the surface expression level
and structural integrity of wild-type and mutant AT1a recep-
tors, transiently expressed in COS-7 cells, the binding of the
Ang II antagonist [Sar1,Ile8]Ang II was measured at 4‡C.
Scatchard analysis of the data showed that the Kd values of
the mutant receptors were comparable to that of the wild-type
AT1a receptor (in nM: wild-type: 2.6 þ 0.6; v319: 2.2 þ 0.5;
v315: 1.9 þ 0.2; v311: 2.2 þ 0.1; v310: 2.3 þ 0.3; v309:
1.9 þ 0.3; n = 3). These data suggest that the integrity of the
receptor was not compromised by these mutations, since the
complex structure of the binding site for the peptide ligand
remained intact. Scatchard analysis of these data also showed
that deletions of the cytoplasmic tail caused a progressive
decrease of surface expression (Fig. 2). The reduced expres-
sion level of the v315 mutant indicates that structures in the
cytoplasmic tail distal to position 314 are required for the
maximal level of receptor expression. Removal of 6 additional
amino acids (v309) further reduced expression to 4.3 þ 0.7%
(n = 3) of that of the wild-type receptor, and deletion of one
additional amino acid, Lys308, caused complete loss of cell-
surface receptors.
These data suggest that the membrane-proximal region of
the cytoplasmic tail is also required for normal AT1a receptor
folding and surface expression in COS-7 cells. The reduced
expression levels of the truncated AT1a receptors were consis-
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Fig. 1. The region of the carboxyl-terminal tail adjacent to the seventh transmembrane helix of the AT1a receptor (positions 307^319) was ana-
lyzed in this study. The one letter codes of amino acids in this region and the positions of the mutated amino acids are shown. The putative
glycosylation sites are also indicated.
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tent with ¢ndings of studies on other GPCRs, in which trun-
cation of the membrane-proximal region reduced receptor ex-
pression levels [12,13,19^22]. Deletion of the cytoplasmic tail
of the human AT1 receptor at position Lys310 reduced the
expression of the receptor in COS-7 cells [24]. The average
expression level of the v315 mutant rat AT1a receptor was
also reduced in permanently transfected CHO cells, but
some of the individual colonies exhibited relatively high ex-
pression levels [23]. This may account for the relatively high
expression levels of cytoplasmic tail deletion mutant AT1a
receptors observed in a recent study on permanently trans-
fected CHO cells [30].
Although our data do not provide evidence for the mecha-
nism by which tail truncations a¡ect receptor expression level,
several explanations for this e¡ect have been proposed. Stud-
ies on mutant rhodopsins have indicated that truncations of
the carboxyl-terminal region of the molecule interfere with
transport of the receptor from the endoplasmic reticulum,
and with membrane insertion of the molecule [35]. A recent
study on the H2 histamine receptor reported that although
there was no detectable ligand binding after truncation of
the cytoplasmic tail adjacent to the membrane domain, syn-
thesis of the mutant receptor mRNA was still observed, sug-
gesting that the carboxyl-terminally truncated receptor is not
e⁄ciently synthesized, transported, or inserted into the mem-
brane [21]. Similar mechanisms may operate in AT1 receptors,
since normal mRNA level and reduced expression of the v310
mutant human AT1 receptor was observed in transiently
transfected COS-7 cells [24]. However, increased degradation
of the truncated receptor molecules is an alternative possibil-
ity that cannot be excluded at this stage.
3.2. Inositol phosphate responses of cytoplasmic tail truncated
mutant AT1a receptors
Transiently transfected COS-7 cells were prelabeled with
[3H]inositol, and after LiCl pretreatment the cells were stimu-
lated with Ang II for 20 min as described in Section 2. To
evaluate the G protein coupling of wild-type and mutant AT1a
receptors maximally e¡ective concentration (1 WM) of Ang II
was used in these experiments [33]. With the exception of the
v319 mutant, all of the cytoplasmic tail deletion-mutant AT1a
receptors showed reduced inositol phosphate responses after
Ang II stimulation (Fig. 3A). The v319 mutant receptor was
previously shown to mediate inositol phosphate responses
comparable to those of the wild-type receptor [26]. The re-
duced inositol-phosphate responses of the v309, v310, v311
and v315 mutant receptors (Fig. 3A) are consistent with our
earlier observation that inositol phosphate signaling in this
system depends on the receptor expression level [33]. After
normalization to the receptor expression level [33], the inositol
phosphate responses for the truncated receptors were higher
than those of the wild-type receptor (Fig. 3B). A similar ¢nd-
ing has been reported in the truncated neurokinin-2 receptor,
and was attributed to impaired phosphorylation and desensi-
tization of the receptor [15]. This mechanism is probably re-
sponsible for the consistently higher inositol phosphate re-
sponses of the v309 to v319 mutant AT1a receptors. Such
deletions eliminate the serine-threonine rich sequences of the
cytoplasmic tail, which are the major targets for phosphoryl-
FEBS 20276 29-5-98
Fig. 2. Surface expression levels of wild-type and deletion mutant
AT1a receptors were calculated by Scatchard analysis of
[Sar1,Ile8]Ang II binding to transiently transfected COS-7 cells. The
designation of each truncated mutant receptor represents the posi-
tion of the amino acid that was replaced with a stop codon. Bind-
ing sites of wild-type and mutant AT1a receptors are shown as the
means þ S.E.M. from three independent experiments, each performed
in duplicate. N.D. indicates that no detectable surface expression
was observed.
Fig. 3. Inositol phosphate responses of wild-type and truncated
AT1a receptors (A) were measured as the combined accumulation of
radioactivity in the InsP2 + InsP3 fraction in [3H]inositol prelabeled
and LiCl (10 mM, 30 min) pretreated COS-7 cells after stimulation
with 1 WM Ang II for 20 min. B: Data were normalized to the
number of expressed extracellular binding sites for each mutant,
and are shown as percent of the wild-type response. Data are shown
as means þ S.E.M. from three independent experiments, each per-
formed in duplicate.
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ation and desensitization of many GPCRs [17,36]. In accord-
ance with this suggestion, it has been shown that protein
kinase C-mediated desensitization of the AT1a receptor de-
pends on the presence of the cytoplasmic tail [28].
In a recent report, the inositol phosphate responses medi-
ated by v314 and larger deletion mutant AT1a receptors were
found to be markedly impaired after 10 s stimulation with
Ang II [30]. The present ¢ndings, in accordance with a study
on the v310 mutant human AT1 receptor [24], demonstrate
that inositol phosphate accumulation is detectable after 20 min
stimulation of the v309 mutant receptor in the presence of
LiCl. A possible explanation for the impaired signaling de-
tected after 10 s of Ang II stimulation is the slower kinetics
of the inositol phosphate responses of the mutant receptors,
similar to earlier reports on the function of Tyr302 in the AT1a
receptor [33,37,38].
3.3. [Sar1,Ile8]Ang II binding to KKFKK(307^311)AAAAA,
KKFKK(307^311)AAFAA, KK(310^311)AA, F309A and
v309 mutant AT1a receptors
The membrane-proximal region of the cytoplasmic tail, ad-
jacent to the seventh transmembrane helix (TM7), contains
conserved structural elements. In a published collection of
GPCRs [7], 84% of the mammalian receptors, excluding the
odorant receptors, contained a conserved phenylalanine resi-
due 3^5 amino acids away from the predicted boundary of
TM7. Another conserved feature of this region is the accumu-
lation of positively charged amino acids adjacent to this con-
served phenylalanine. Of 59 mammalian GPCRs, all except
the C5a anaphylatoxin receptor contained at least 1 lysine
or arginine residue in the region corresponding to positions
307^311 of the AT1 receptor, and 65% had two or more
residues in this region.
Our data showed that the v311 and v315 mutant receptors
were similar in all tested parameters, but deletion of addition-
al residues progressively decreased the receptor expression,
suggesting the importance of this conserved domain, located
proximal from position 311. To study the role of this region
(Lys307-Lys308-Phe309-Lys310-Lys311) in AT1a receptor func-
tion, alanine substitution mutant receptors were created. No
[Sar1,Ile8]Ang II binding was detected after replacement of all
¢ve amino acids with alanine (KKFKK(307^311)AAAAA) or
elimination of the positive charge of the region by substituting
the four lysine residues with alanine (KKFKK(307^311)AA-
FAA) (Fig. 4A). These ¢ndings are consistent with the above-
suggested function of this region in receptor expression.
To further analyze the function of the conserved amino
acids, two more mutants were constructed. In mutant
KK(310^311)AA, Lys310 and Lys311 were replaced with ala-
nine to remove part of the positive charge in this region, and
an F309A mutant AT1a receptor was created to study the role
of the conserved phenylalanine residue. The binding a⁄nities
of the KK(310^311)AA and F309A mutant AT1a receptors
for the peptide antagonist [Sar1,Ile8]Ang II were 1.6 þ 0.2
and 1.7 þ 0.1 nM (n = 3), similar to the a⁄nity of the wild-
type receptor (2.4 þ 0.7 nM, n = 3) as determined in the same
experiments. However, the expression levels of the mutant
receptors were markedly reduced (Fig. 4A). Cells expressing
F309A or KK(310^311)AA mutant receptors also showed re-
duced inositol phosphate accumulation after agonist stimula-
tion (56.8 þ 3.6% and 42.9 þ 2.4% of that of the wild-type
AT1a receptor, respectively). Considering the lower expression
levels of these receptors, we concluded that Phe309, Lys310, and
Lys311 do not have a major role in the inositol phosphate
signal generation of the AT1a receptor.
Based on these data, the major loss of expression caused by
truncating the AT1a receptor at position 309 has at least two
components. In addition to the role of Phe309 and the sur-
rounding positively charged residues in the regulation of the
expression level, the lower expression level of the v315 mutant
receptor indicates that additional elements, located distal to
position 314, are also required for maximal receptor expres-
sion.
The internalization kinetics of the alanine substitution
KK(310^311)AA and F309A mutant receptors did not di¡er
from those of the wild-type receptor (Fig. 4B). These ¢ndings
con¢rm that the structure of the receptor, and its agonist-
induced activation, are not a¡ected by mutations in the mem-
brane-proximal region of the cytoplasmic tail. The strongly
impaired internalization kinetics of the v309 mutant are con-
sistent with earlier ¢ndings on the role of the cytoplasmic tail
in AT1 receptor internalization [23,25^28].
In conclusion, these data provide further evidence that the
cytoplasmic tail is required for normal expression and inter-
nalization of the AT1a receptor. The present ¢ndings also
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Fig. 4. Surface expression levels (A) of wild-type, v309, F309A,
KK(310^311)AA (KK/AA), KKFKK(307^311)AAAAA (AAAAA)
and KKFKK(307^311)AAFAA (AAFAA) mutant AT1a receptors
were calculated by Scatchard analysis of [Sar1,Ile8]Ang II binding to
transiently transfected COS-7 cells. Data are shown as percent of
the expressed wild-type AT1a receptor binding sites (n = 3). N.D. in-
dicates that no detectable surface expression was observed. Internal-
ization kinetics (B) of the wild-type (b), F309A (O), KK/AA (E)
and v309 (a) mutant AT1a receptors were measured after addition
of 125I-Ang II at 0 min as described in Section 2. Internalized bind-
ing is shown as percent of total speci¢c binding of each sample.
Data represent the means þ S.E.M. from three independent experi-
ments, each performed in duplicate.
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demonstrate that the conserved Phe309 residue, and the adja-
cent positively charged amino acids in the membrane-proxi-
mal region of the cytoplasmic tail, are selectively involved in
the regulation of the receptor expression level without a¡ect-
ing receptor internalization or inositol phosphate signal gen-
eration.
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